Testing Effect of InterventionPhase 3NCT00321126
Zinc Supplementation in Shigella Patients
A Phase 3 study testing Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks. in people with Testing Effect of Intervention, run by International Centre for Diarrhoeal Disease Research, Bangladesh.
Trial summary
Shigellosis is a major cause of morbidity and mortality in young children in Bangladesh and other developing countries. Further, the increasing emergence of resistance to a wide range of antibiotics is of great concern. Read more about this study
- Who is it for?
- Ages 12 to 59 months
- Conditions the study is for
- Testing Effect of Intervention
- What is being tested?
- Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
- How many people
- 56 participants
- Where
- No sites listed yet
- Study dates
- Jan 1999to Apr 2002
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 59 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age between 12-59 months
- Moderate malnutrition (61-75% Weight / Age - NCHS Median)
- Duration of diarrhoea of 5 days
- Culture confirmed shigella spp in stool on enrolment
Who cannot join
- Measles infection in the past six months
- Presence of obvious systemic illnesses
- Severe malnutrition
- Residence in a location requiring a journey of>2 hour from the Dhaka Hospital of the ICDDR,B
- Refusal to give consent
About this study
Official title: Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery
Shigellosis is a major cause of morbidity and mortality in young children in Bangladesh and other developing countries. Further, the increasing emergence of resistance to a wide range of antibiotics is of great concern. Another major public health problem in Bangladesh is malnutrition, which is closely linked with shigellosis and with a high mortality. In Shigellosis, a heavy nutritional burden is placed on children and vital micronutrients such as vitamin A is lost in the urine. We recently found that the immune response in S. Flexneri infection was lower in children who were severely malnourished (weight-for-age≤65% as a percentage of the National Centre for Health Statistics median) when compared to children with weight-for-age from >65-75%. T cell responses were primarily affected with lowered CD4/CD8 ratios, lowered proliferative responses to T cell mitogens, Conconavalin A (ConA) and phytohaemagglutinin (PHA). However, proliferation of pheripheral blood mononuclear cells (PBMs) was lowered only in the presence of autologous plasma suggesting that a factor(s) in plasma, probably nutritional, rather than a defect in cells themselves was responsible. In children with S. dysenteriae 1 infection, proliferative responses to PHA were similarly lowered in the presence of autologous plasma but inhibition correlated to lowered transferring levels in plasma and not to the weight-for-age of the children. Also severely malnourished children with either S. flexneri or S. dysenteriae 1 infection were more severely ill. These findingings show that immunity in malnourishrd children with shigella infection is impaired which may lead to more severe illness. As zinc has profound effects on immunity as well as clinical outcome in diarrhoeal diseases, it is possible that zinc deficiency may be a factor in reducing immunity and increasing severity of acute illness in malnourished children with shigellosis. In this study, we will investigate the effect of zinc supplementation, in a double blind placebo controlled trial, on inflammatory responses, outcome of acute illness and growth following recovery from acute illness with S. flexneri infection.
Read the detailed description
Study design: The study was a double blind randomised clinical trial using zinc and placebo using multivitamin base.Study subjects: Fifty six children of both sex aged between 12-59 months were studied in the study ward who attended the Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh with shigellosis. The patients were initially screened for the study. Stool samples were examined microscopically and stool was cultured for enteric bacterial pathogens. Children whose stool cultures were positive for shigella species were included in the study. Selection of the patients were based on the following criteria: age between 12-59 months, moderate malnutrition (61-75% Weight / Age - NCHS Median), duration of diarrhoea of 5 days, and culture confirmed shigella spp in stool on enrolment. Measurements of weight and length (height) were performed by using the WHO Manual28. The exclusion criteria were as follows: measles infection in the past six months; presence of obvious systemic illnesses, such as pneumonia, meningitis, septicaemia, leukemoid reaction, haemolytic uremic syndrome etc; zinc supplementation; severe malnutrition; residence in a location requiring a journey of > 2 hour from the Dhaka Hospital of the ICDDR,B ; and refusal to give consent. Signed informed consent was obtained from the guardian of each paediatric patients before enrolment according to the guidelines of the ethical review committee of the ICDDR,B. The study was conducted between January 1999 -December 2002.Study Groups: There were two study groups, one received zinc acetate with multivitamin syrup and antibiotic i.e. pivmecillinum and the other with placebo and pivmecillinum . Composition of syrup: For both groups, the base syrup or multivitamin syrup was of the same composition. In addition to this, zinc acetate (20 mg elemental Zn/ 5 ml) was mixed in the multivitamin syrup for the zinc supplemented group to receive 20 mg elemental zinc per day.Composition of base/ multivitamin syrup: Every 5 ml of the multivitamin syrup contained the following: vitamin A (3000IU), vitamin D (600 IU), thiamin (1.2 mg), riboflavin (2.0 mg), nicotinamide (6.0 mg) and calcium pantothanate (6 mg).Dose of zinc: Subjects of zinc group received 20 mg elemental zinc as acetate per day in a twice-daily dose for a period of 2 weeks. Methods: A block randomization procedure was performed by using a random table to assign a equal number of patients to the zinc supplemented and placebo group. Twenty eight in each group were allocated to zinc or placebo using block randomization. Double blinding was done by having identical coloured bottles of syrup labeled with serial numbers, which were allocated to the children of the 2 groups chronologically. The zinc syrup containing zinc and the multivitamin was masked for taste and flavor and was indistinguishable in consistency, appearance and taste from the control syrup containing the multivitamin only. The micronutrient supplements were prepared by Acme Laboratories, Dhaka Bangladesh. The experimental group received the zinc syrup containing the multivitamin (the vitamins were given at twice the recommended dietary allowance) in 2 divided doses daily for 2 weeks starting from the day of admission. The comparison group received the same multivitamin syrup alone. All the subjects received pivmecillinum in a dose of 60 mg/kg/day in 4 divided doses for 5 days. In both groups of patients, diarrhea subsided within 3-5 days. During hospitalization all the study children received a standard hospital diet of 100-125 kcal and 3-5 g protein per kg body weight daily in mixed food. When discharged at day-7, their mothers were given the bottles of syrup and were instructed to feed the child with the supplement daily at home for rest 7 days. On the 14th day, a health assistant visited the household, measured the amount of syrup taken and also enquired the mothers about any problems encountered during feeding of syrups. Children were followed up fortnightly for up to 6 months after the onset of diarrhoea to assess morbidity and growth. The following was investigated during the study period -Clinical evaluation: duration of illness, presence of blood in stool, tenesmus, and weight changes.Assessment of growth and growth velocity: Measurements included weight, height, triceps skinfold thickness (TSF) using standard technique (WHO)28. These were done before supplementation and at discharge. After supplementation, children were measured every two weeks at home. Weights were obtained to the nearest 10 g using an electronic digital scale (Secca model 770, Sweden) standarised with 5 and 10 kg standard weights in everyday morning and evening. Recubent length was measured in children less than two years of age using a slide board infantometer (Harpenden, St. Albans, England). In older children, standing height was determined with a Stadiometer . Mean of two consecutive height measurements to the nearest 0.5 cm was recorded as the observe value. Measurements were compared to Median NCHS Standard. Health workers were extensively trained in anthropometric measurements, until minimum intra-individual and inter individual variation was attainted. Statistical Analysis:The data were checked daily at recording by the investigators, cleaned and then entered in microcomputer using SPSS/PC+ (Windows 10.0). Data analysis was performed using SPSS/PC+ (Windows 10.0) and EPI Info (Nutrition)version 3.2.2. The consistency check was done using logical programs. Student and paired t-tests were used when data were normally distributed and non- parametric Mann-Whitney U tests were used when the distribution were skewed. Time sequence of proportions of recovery was compared between two groups using Kaplan Meier survival analysis. Proportions were compared using chi-squared test. Repeated measure analyses of variance were also undertaken to evaluate the changes in weight gain and length gain over the follow-up periods. Statistical significance was accepted at 5 percent level.
- Conditions
- Testing Effect of Intervention
- Being tested
- Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
- Keywords
- Zinc, Shigella, Children, Bangladesh
- Medical subject headings
- Dysentery, Bacillary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.Drug
What is being measured
The primary outcome is the main question the study is designed to answer.
Age
Sex
Weight
Body Mass index
Duration of diarrhoea before admission
Stool volume
Dehydration status
Secondary outcomes (8)
In blood: total and differential WBC counts,C-reactive protein, albumin, serum electrolytes and creatinine concentration
Quantitation of luminal neutriphils
Immune response
Duration of recovery
Presence of blood and mucous in stool
Weight gain
Length gain
Episodes of illness during follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2006 (estimated)
- Study startJan 1999
- Study completionApr 2002
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Testing Effect of InterventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Enrolment
- 56 participants
Sponsor and investigators
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska Institutet
- Investigators
- Swapan Kumar Roy, MBBS, M.Sc, Ph. D, Principal investigator, International Centre for Diarrhoeal Disease Research, Bangladesh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00321126
- Sponsor's protocol ID
- 97-020
- Status last verified
- May 2006
- First submitted
- 2 May 2006
- Last updated
- 3 May 2006
- Results posted
- No
Publications
Roy SK, Raqib R, Khatun W, Azim T, Chowdhury R, Fuchs GJ, Sack DA. Zinc supplementation in the management of shigellosis in malnourished children in Bangladesh. Eur J Clin Nutr. 2008 Jul;62(7):849-55. doi: 10.1038/sj.ejcn.1602795. Epub 2007 Jun 6.
PubMed 17554249
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery
- ClinicalTrials.gov ID
- NCT00321126
- Acronym / sponsor ID
- 97-020
- Conditions
- Testing Effect of Intervention
- Keywords
- Zinc, Shigella, Children, Bangladesh
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, BangladeshUniversity, hospital or other
- Collaborators
- Karolinska Institutet
- Study start
- Jan 1999
- Study completion
- Apr 2002
- First posted
- 3 May 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Shigellosis is a major cause of morbidity and mortality in young children in Bangladesh and other developing countries. Further, the increasing emergence of resistance to a wide range of antibiotics is of great concern. Another major public health problem in Bangladesh is malnutrition, which is closely linked with shigellosis and with a high mortality. In Shigellosis, a heavy nutritional burden is placed on children and vital micronutrients such as vitamin A is lost in the urine. We recently found that the immune response in S. Flexneri infection was lower in children who were severely malnourished (weight-for-age≤65% as a percentage of the National Centre for Health Statistics median) when compared to children with weight-for-age from >65-75%. T cell responses were primarily affected with lowered CD4/CD8 ratios, lowered proliferative responses to T cell mitogens, Conconavalin A (ConA) and phytohaemagglutinin (PHA). However, proliferation of pheripheral blood mononuclear cells (PBMs) was lowered only in the presence of autologous plasma suggesting that a factor(s) in plasma, probably nutritional, rather than a defect in cells themselves was responsible. In children with S. dysenteriae 1 infection, proliferative responses to PHA were similarly lowered in the presence of autologous plasma but inhibition correlated to lowered transferring levels in plasma and not to the weight-for-age of the children. Also severely malnourished children with either S. flexneri or S. dysenteriae 1 infection were more severely ill. These findingings show that immunity in malnourishrd children with shigella infection is impaired which may lead to more severe illness. As zinc has profound effects on immunity as well as clinical outcome in diarrhoeal diseases, it is possible that zinc deficiency may be a factor in reducing immunity and increasing severity of acute illness in malnourished children with shigellosis. In this study, we will investigate the effect of zinc supplementation, in a double blind placebo controlled trial, on inflammatory responses, outcome of acute illness and growth following recovery from acute illness with S. flexneri infection.
Detailed description
Study design: The study was a double blind randomised clinical trial using zinc and placebo using multivitamin base.Study subjects: Fifty six children of both sex aged between 12-59 months were studied in the study ward who attended the Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh with shigellosis. The patients were initially screened for the study. Stool samples were examined microscopically and stool was cultured for enteric bacterial pathogens. Children whose stool cultures were positive for shigella species were included in the study. Selection of the patients were based on the following criteria: age between 12-59 months, moderate malnutrition (61-75% Weight / Age - NCHS Median), duration of diarrhoea of 5 days, and culture confirmed shigella spp in stool on enrolment. Measurements of weight and length (height) were performed by using the WHO Manual28. The exclusion criteria were as follows: measles infection in the past six months; presence of obvious systemic illnesses, such as pneumonia, meningitis, septicaemia, leukemoid reaction, haemolytic uremic syndrome etc; zinc supplementation; severe malnutrition; residence in a location requiring a journey of > 2 hour from the Dhaka Hospital of the ICDDR,B ; and refusal to give consent. Signed informed consent was obtained from the guardian of each paediatric patients before enrolment according to the guidelines of the ethical review committee of the ICDDR,B. The study was conducted between January 1999 -December 2002.Study Groups: There were two study groups, one received zinc acetate with multivitamin syrup and antibiotic i.e. pivmecillinum and the other with placebo and pivmecillinum . Composition of syrup: For both groups, the base syrup or multivitamin syrup was of the same composition. In addition to this, zinc acetate (20 mg elemental Zn/ 5 ml) was mixed in the multivitamin syrup for the zinc supplemented group to receive 20 mg elemental zinc per day.Composition of base/ multivitamin syrup: Every 5 ml of the multivitamin syrup contained the following: vitamin A (3000IU), vitamin D (600 IU), thiamin (1.2 mg), riboflavin (2.0 mg), nicotinamide (6.0 mg) and calcium pantothanate (6 mg).Dose of zinc: Subjects of zinc group received 20 mg elemental zinc as acetate per day in a twice-daily dose for a period of 2 weeks. Methods: A block randomization procedure was performed by using a random table to assign a equal number of patients to the zinc supplemented and placebo group. Twenty eight in each group were allocated to zinc or placebo using block randomization. Double blinding was done by having identical coloured bottles of syrup labeled with serial numbers, which were allocated to the children of the 2 groups chronologically. The zinc syrup containing zinc and the multivitamin was masked for taste and flavor and was indistinguishable in consistency, appearance and taste from the control syrup containing the multivitamin only. The micronutrient supplements were prepared by Acme Laboratories, Dhaka Bangladesh. The experimental group received the zinc syrup containing the multivitamin (the vitamins were given at twice the recommended dietary allowance) in 2 divided doses daily for 2 weeks starting from the day of admission. The comparison group received the same multivitamin syrup alone. All the subjects received pivmecillinum in a dose of 60 mg/kg/day in 4 divided doses for 5 days. In both groups of patients, diarrhea subsided within 3-5 days. During hospitalization all the study children received a standard hospital diet of 100-125 kcal and 3-5 g protein per kg body weight daily in mixed food. When discharged at day-7, their mothers were given the bottles of syrup and were instructed to feed the child with the supplement daily at home for rest 7 days. On the 14th day, a health assistant visited the household, measured the amount of syrup taken and also enquired the mothers about any problems encountered during feeding of syrups. Children were followed up fortnightly for up to 6 months after the onset of diarrhoea to assess morbidity and growth. The following was investigated during the study period -Clinical evaluation: duration of illness, presence of blood in stool, tenesmus, and weight changes.Assessment of growth and growth velocity: Measurements included weight, height, triceps skinfold thickness (TSF) using standard technique (WHO)28. These were done before supplementation and at discharge. After supplementation, children were measured every two weeks at home. Weights were obtained to the nearest 10 g using an electronic digital scale (Secca model 770, Sweden) standarised with 5 and 10 kg standard weights in everyday morning and evening. Recubent length was measured in children less than two years of age using a slide board infantometer (Harpenden, St. Albans, England). In older children, standing height was determined with a Stadiometer . Mean of two consecutive height measurements to the nearest 0.5 cm was recorded as the observe value. Measurements were compared to Median NCHS Standard. Health workers were extensively trained in anthropometric measurements, until minimum intra-individual and inter individual variation was attainted. Statistical Analysis:The data were checked daily at recording by the investigators, cleaned and then entered in microcomputer using SPSS/PC+ (Windows 10.0). Data analysis was performed using SPSS/PC+ (Windows 10.0) and EPI Info (Nutrition)version 3.2.2. The consistency check was done using logical programs. Student and paired t-tests were used when data were normally distributed and non- parametric Mann-Whitney U tests were used when the distribution were skewed. Time sequence of proportions of recovery was compared between two groups using Kaplan Meier survival analysis. Proportions were compared using chi-squared test. Repeated measure analyses of variance were also undertaken to evaluate the changes in weight gain and length gain over the follow-up periods. Statistical significance was accepted at 5 percent level.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
Who may qualify
- Ages
- 12 to 59 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Age between 12-59 months
- Moderate malnutrition (61-75% Weight / Age - NCHS Median)
- Duration of diarrhoea of 5 days
- Culture confirmed shigella spp in stool on enrolment
Key exclusion criteria (5 listed)
- Measles infection in the past six months
- Presence of obvious systemic illnesses
- Severe malnutrition
- Residence in a location requiring a journey of>2 hour from the Dhaka Hospital of the ICDDR,B
- Refusal to give consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks. | Drug | – |
Primary outcome
Age
Sex
Weight
Body Mass index
Duration of diarrhoea before admission
Stool volume
Dehydration status
8 secondary outcomes
In blood: total and differential WBC counts,C-reactive protein, albumin, serum electrolytes and creatinine concentration
Quantitation of luminal neutriphils
Immune response
Duration of recovery
Presence of blood and mucous in stool
Weight gain
Length gain
Episodes of illness during follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2006.
- Derived from this study: PubMed 17554249Roy SK, Raqib R, Khatun W, Azim T, Chowdhury R, Fuchs GJ, Sack DA. Zinc supplementation in the management of shigellosis in malnourished children in Bangladesh. Eur J Clin Nutr. 2008 Jul;62(7):849-55. doi: 10.1038/sj.ejcn.1602795. Epub 2007 Jun 6.
Related trials for Testing Effect of Intervention
Enrolling by invitation
ProFoUND PCC= A Program For a Userbased Nursing Development in Person-Centered Care, is a Project That Aims to Develop, Test and Evaluate Effects of a Co-created Intervention to Increase Person-centred Care in Residential Care Settings for Older People.
To Develop, Test, Implement and Evaluate a Model for Person-centred Care for Older People at Two Academic Residential Care Facilities
Recruiting
Internet-Based EMDR Flash Intervention for Test Anxiety in University Students
Test Anxiety
Recruiting
Effect of Video -Based vs Standard ınformation on Maternal Anxiety and Procedure Decision in Pregnant Woman Offered Amniocentesis or Cvs
Maternal Anxiety, Prenatal Diagnosis
Recruiting
Mindful Moms, Mindful Meals (MMMM) Study
Nutrition in Early Infancy, Nutrition Habits
Not yet recruiting
Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing
Cervical Cancer, HPV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Swapan Kumar Roy, MBBS, M.Sc, Ph. D principal investigator
International Centre for Diarrhoeal Disease Research, Bangladesh
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks. in people with Testing Effect of Intervention, run by International Centre for Diarrhoeal Disease Research, Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 May 2006. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Age. The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00321126, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2006.